News

Company   ImmuPharma PLC
TIDM         IMM
Headline     INTERIM RESULTS ANNOUNCEMENT
Released    07:00 30-Sep-2011
Number     2533P07

FOR IMMEDIATE RELEASE

London, 30 September 2011

INTERIM RESULTS ANNOUNCEMENT
For the six months ended 30 June 2011

ImmuPharma plc (LSE:IMM) ("Immupharma" or the "Company" or the "Group"), the specialist discovery and development pharmaceutical company is pleased to announce its interim results for the six months ended 30 June 2011.

INTERIM HIGHLIGHTS

Cephalon, Inc (Cephalon), ImmuPharma's licensee for Rigerimod (Lupuzor^TM), continues to progress its Phase IIb trial in US and European lupus patients. This study has been designed to provide US-based investigators and the US FDA with clinical data obtained mainly in the USA. This data will be part of the package submitted to the FDA and other regulatory authorities for approval. We plan to provide an update on this trial in conjunction with Cephalon announcing these results. Positive Phase IIb data from outside the USA has previously been announced. ImmuPharma look forward to providing an update on Lupuzor^TM's progress following the finalisation of the acquisition of Cephalon by Teva Pharmaceuticals.
The Phase I/IIa trial of IPP-204106, ImmuPharma's anti-cancer compound with a novel and promising mechanism of action, continues to progress in cancer patients. A scientific paper on IPP-204106 was published in the prestigious medical journal of the American Association for Cancer Research.
Strong cash position of £14.3m.
Basic and diluted loss per share were 2.59p and 2.59p respectively (30 June 2010: basic and diluted loss per share 0.10p and 0.10p respectively)Basic and diluted loss per share were both 2.44p (31 December 2009: basic and diluted earnings per share10.46p and 9.99p respectively).

Commenting on the progress to date and the outlook for ImmuPharma, Dimitri Dimitriou, Chief Executive Officer, said:

"The first half of 2011 has seen ImmuPharma build on the success of 2010 with Cephalon, our licensee for Lupuzor^TM, moving ahead with a large trial in the US. We look forward to providing an update on Lupuzor^TM's progress once Teva's acquisition of Cephalon is complete. In parallel, we are focusing our own efforts on our promising cancer drug and are pleased to have seen encouraging results so far and to have achieved publication in the journal of the American Association for Cancer Research. We look forward to building on this success during the rest of 2011 and in the coming years."

Richard Warr, ImmuPharma's Chairman added:

"ImmuPharma has two potential blockbuster drugs in the clinic, Lupuzor^TM and our cancer compound, IPP-204106. We look forward to providing an update on Lupuzor^TM following the imminent finalisation of Teva's acquisition of Cephalon. Moreover, ImmuPharma is pleased to report a strong balance sheet, controlled expenditure and a robust cash position."

Full report and announcement:

For further information please contact:

ImmuPharma PLC +44 20 7152 4080

Dimitri Dimitriou, Chief Executive Officer
Richard Warr, Chairman
Tracy Weimar, Vice President, Operations

Buchanan Communications +44 20 7466 5000

Lisa Baderoon, Mark Court

Panmure Gordon & Co., NOMAD & Broker +44 20 7459 3600

Andrew Burnett

Espirito Santo Investment Bank, Joint Broker +44 20 7456 9191

James Bromhead


Home About ImmuPharma Lead compounds Discovery pipeline Management team News For Investors Contact us	News Company ImmuPharma PLC TIDM IMM Headline INTERIM RESULTS ANNOUNCEMENT Released 07:00 30-Sep-2011 Number 2533P07 FOR IMMEDIATE RELEASE London, 30 September 2011 INTERIM RESULTS ANNOUNCEMENT For the six months ended 30 June 2011 ImmuPharma plc (LSE:IMM) ("Immupharma" or the "Company" or the "Group"), the specialist discovery and development pharmaceutical company is pleased to announce its interim results for the six months ended 30 June 2011. INTERIM HIGHLIGHTS Cephalon, Inc (Cephalon), ImmuPharma's licensee for Rigerimod (Lupuzor^TM), continues to progress its Phase IIb trial in US and European lupus patients. This study has been designed to provide US-based investigators and the US FDA with clinical data obtained mainly in the USA. This data will be part of the package submitted to the FDA and other regulatory authorities for approval. We plan to provide an update on this trial in conjunction with Cephalon announcing these results. Positive Phase IIb data from outside the USA has previously been announced. ImmuPharma look forward to providing an update on Lupuzor^TM's progress following the finalisation of the acquisition of Cephalon by Teva Pharmaceuticals. The Phase I/IIa trial of IPP-204106, ImmuPharma's anti-cancer compound with a novel and promising mechanism of action, continues to progress in cancer patients. A scientific paper on IPP-204106 was published in the prestigious medical journal of the American Association for Cancer Research. Strong cash position of £14.3m. Basic and diluted loss per share were 2.59p and 2.59p respectively (30 June 2010: basic and diluted loss per share 0.10p and 0.10p respectively)Basic and diluted loss per share were both 2.44p (31 December 2009: basic and diluted earnings per share10.46p and 9.99p respectively). Commenting on the progress to date and the outlook for ImmuPharma, Dimitri Dimitriou, Chief Executive Officer, said: "The first half of 2011 has seen ImmuPharma build on the success of 2010 with Cephalon, our licensee for Lupuzor^TM, moving ahead with a large trial in the US. We look forward to providing an update on Lupuzor^TM's progress once Teva's acquisition of Cephalon is complete. In parallel, we are focusing our own efforts on our promising cancer drug and are pleased to have seen encouraging results so far and to have achieved publication in the journal of the American Association for Cancer Research. We look forward to building on this success during the rest of 2011 and in the coming years." Richard Warr, ImmuPharma's Chairman added: "ImmuPharma has two potential blockbuster drugs in the clinic, Lupuzor^TM and our cancer compound, IPP-204106. We look forward to providing an update on Lupuzor^TM following the imminent finalisation of Teva's acquisition of Cephalon. Moreover, ImmuPharma is pleased to report a strong balance sheet, controlled expenditure and a robust cash position." Full report and announcement: For further information please contact: ImmuPharma PLC +44 20 7152 4080 Dimitri Dimitriou, Chief Executive Officer Richard Warr, Chairman Tracy Weimar, Vice President, Operations Buchanan Communications +44 20 7466 5000 Lisa Baderoon, Mark Court Panmure Gordon & Co., NOMAD & Broker +44 20 7459 3600 Andrew Burnett Espirito Santo Investment Bank, Joint Broker +44 20 7456 9191 James Bromhead ©2010 London Stock Exchange plc. All rights reserved